Navigation Links
CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone

ich provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for its product candidates, its formulation efforts, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, risks associated with developing modified-release formulations of its product candidates, assumptions regarding the mechanism of action of our product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(C) 2007 CombinatoRx, Incorporated. All rights reserved.

Contact

CombinatoRx, Incorporated
Robert Forrester,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... 8 Group Practice Forum (GPF), an independent network ... Fromer-GPF Patient Journey , a proprietary workflow solution designed ... patient care.  The Journey was developed by the ... FAAFP, who also serves as Assistant Clinical Professor of Family ...
... Protectus Medical Devices, Inc. (OTCQB: PTMD), developer and marketer of innovative safety ... US Patent and Trademark Office on its patent application describing a spring-activated, ... it becoming the gold standard in safety syringe devices.  , ... Dr. John Salstrom , CEO, ...
Cached Medicine Technology:Group Practice Forum Launches Fromer-GPF Patient Journey Providing Physicians with Simple Solutions to Improve Patient Care 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 3
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... discussions with FDA -, MENLO PARK, Calif., Dec. ... of customizable drug-eluting stent (DES),systems, today announced that it ... for CE Mark approval of its Custom NX DES,System., ... dossier and the,drug formulation submission from Biosensors International Group. ...
... ST. PAUL (December 26, 2007) University of Minnesota ... researchers have discovered a new fast-acting antidote to cyanide ... those who are exposed to the chemical namely ... cyanide antidotes work slowly and are ineffective when administered ...
... hay fever and other allergic reactions, by preventing the ... by scientists. Researchers hope their finding, published today (Thursday ... allow therapies to be developed that treat allergies by ... a gene known as GATA-3 can block the development ...
... Dec. 26 A lot of Americans take advantage ... to lose weight and live,healthier. There may be a ... that work focus on healthy long-term lifestyle changes., ... Registered journalists can access video, audio, text, graphics ...
... cell research to needle exchanges to medical marijuana and ... science, according to a new book by a leading ... Weill Cornell Medical College. , "Truth, Lies, and Public ... Collide" (Praeger Press, 2007) is authored by Dr. Madelon ...
... results are promising, they don,t address benefits of drug ... treatment that wipes out abnormal heart tissue reduces the ... implanted after heart attacks, a new trial showed. , ... it slips into abnormal rhythms, they are desirable to ...
Cached Medicine News:Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:U of M researchers discover fast-acting cyanide antidote 2Health News:Fight against hay fever and other allergies helped by new immune system discovery 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
CRP Liquid Conrtols level 3...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Medicine Products: